Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | FORTY | ZBIO |
|---|---|---|
| Price | $118.15 | $27.83 |
| Change today | ▲ 4.09% | ▼ 1.64% |
| Market cap | $1.81B | $1.81B |
| Return, 3 months | +6.0% | +0.5% |
| Return, year to date | -21.2% | -23.4% |
| Return, 1 year | -7.0% | +20.8% |
| P/E (TTM) | 3.0 | -2.9 |
| P/B | 1.5 | 7.3 |
| P/E percentile vs own 5y | 5th | – |
| Dividend yield | 0.88% | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | – |
| Analyst target vs. price | – | +61.0% |
| Analyst buy share | – | 80% |
| RSI (14) | 54 | 40 |
| 30-day volatility | 29.0% | 54.5% |
| Max drawdown, 1 year | -42.0% | -64.8% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
